好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Community-based Brain Health Screening Through Portable MRI and Brain-age Modeling
Global Health and Neuroepidemiology
P5 - Poster Session 5 (11:45 AM-12:45 PM)
20-002

To develop a portable MRI brain-age model for community brain health screening and examine its associations with vascular risk factors.

Brain-age modeling estimates biological brain age from MRI-derived volumes, providing a quantitative marker of neurovascular health. Portable MRI (pMRI) enables imaging outside of traditional hospital settings, offering opportunities for large-scale, accessible brain health screening. By integrating pMRI with data-driven modeling, we aimed to establish a scalable approach to monitor brain health across community sites.

T2-weighted pMRI scans were analyzed from 1,311 participants (mean age 50.8 ± 18.8 years, 70.6% female) across 14 community sites in Arizona and Southern California. Sixteen regional brain volumes were segmented with WMH-Synthseg, a machine-learning tool optimized for pMRI. These volumes were entered into a LASSO regression model (5-fold cross-validation) to predict chronological age. Performance was evaluated using mean absolute error. Multivariable associations between the corrected brain-age gap and vascular risk factors were evaluated. Additional analyses examined predictors of extreme deviation.

The model achieved a mean absolute error of 8.7 years (95% CI, 8.3-9.0) and R2=0.68 (95% CI, 0.65-0.70). In multivariable analyses, BMI, high blood pressure, and high cholesterol were associated with greater brain-age deviation, while sex, diabetes, and race were not. Participants with a brain-age gap ≥10 years older were more likely to have high cholesterol (OR=2.2[1.50-3.10], p<0.001), whereas those with a brain-age gap ≥10 years younger were more often female (OR=1.6[1.10-2.30], p=0.01) and did not have high blood pressure (OR=0.64[0.46-0.90], p<0.01). No single demographic strongly predicted deviation magnitude (R2=0.007).

Portable MRI brain-age modeling offers accessible estimates of biological brain-age using low-field data acquired in community settings. The model identifies expected neuroanatomical aging patterns and vascular correlates of accelerated brain aging. These results support the feasibility of population-level brain-health screening with portable MRI and highlight the possibility to track modifiable risk factors in real-world environments.

Authors/Disclosures
Hailey Brigger
PRESENTER
Ms. Brigger has nothing to disclose.
Ian P. Johnson Mr. Johnson has nothing to disclose.
Annabelle Shanks, BS Ms. Shanks has nothing to disclose.
Steph Maynez Ms. Maynez has nothing to disclose.
Alison Champagne Mrs. Champagne has nothing to disclose.
Cyprien Rivier, MD (Yale University) Dr. Rivier has nothing to disclose.
Jennifer Johnson, NP Mrs. Johnson has nothing to disclose.
Matt De Both Mr. De Both has nothing to disclose.
Danielle Metz, CCRP Ms. Metz has nothing to disclose.
Darian Chambers, Clinical Research Coordinator Mr. Chambers has nothing to disclose.
Calla Price Ms. Price has received personal compensation for serving as an employee of TGen.
Yareli Barraza Miss Barraza has nothing to disclose.
Sarah Moore Ms. Moore has nothing to disclose.
Ignazio Piras, PhD Mr. Piras has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer.
Shaily Agrawal, MBBS Dr. Agrawal has nothing to disclose.
Jua Iglesias Gonzalez (Martinos Center for Biomedical Imaging) Jua Iglesias Gonzalez has nothing to disclose.
Annabel Sorby-Adams (Massachusetts General Hospital and Harvard Medical School) Annabel Sorby-Adams has nothing to disclose.
W. T. Kimberly, MD, PhD (Massachusetts General Hospital) Dr. Kimberly has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astrocyte Pharmaceuticals. Dr. Kimberly has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acasti Pharma. Dr. Kimberly has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Dr. Kimberly has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Stryker. Dr. Kimberly has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurotherapeutics. Dr. Kimberly has stock in Woolsey Pharmaceuticals. Dr. Kimberly has stock in Acasti Pharma. The institution of Dr. Kimberly has received research support from NIH. The institution of Dr. Kimberly has received research support from Hyperfine, Inc.. The institution of Dr. Kimberly has received research support from Alzheimer's Association. Dr. Kimberly has received intellectual property interests from a discovery or technology relating to health care.
Adam De Havenon, MD, FAAN (Yale University) Dr. De Havenon has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novo Nordisk. Dr. De Havenon has or had stock in Certus.Dr. De Havenon has or had stock in TitinKM. The institution of Dr. De Havenon has received research support from NIH/NINDS. Dr. De Havenon has received publishing royalties from a publication relating to health care.
Matthew Huentelman (TGen) Matthew Huentelman has nothing to disclose.
Kevin N. Sheth, MD, FAAN (Yale UniversityDivision of Neuro and Critical Care) Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ceribell. Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zoll. Dr. Sheth has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NControl. Dr. Sheth has received stock or an ownership interest from Astrocyte. Dr. Sheth has received stock or an ownership interest from Alva. The institution of Dr. Sheth has received research support from Biogen. The institution of Dr. Sheth has received research support from Novartis. The institution of Dr. Sheth has received research support from Bard. The institution of Dr. Sheth has received research support from Hyperfine. Dr. Sheth has received intellectual property interests from a discovery or technology relating to health care.